H Golding

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies
    H Golding
    Division of Viral Products, CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 15:149-59. 1999
  2. pmc Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Virol 79:6791-800. 2005
  3. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
  4. ncbi request reprint Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM 457 Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Bethesda, MD 20892, USA
    Virology 339:164-75. 2005
  5. ncbi request reprint CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Biol Chem 280:29570-7. 2005
  6. ncbi request reprint Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A, Rm 1A21, 8800 Rockville Pike, Bethesda, MD, 20892, USA
    Blood 102:3280-6. 2003
  7. pmc Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Room 1A21, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6780-90. 2002
  8. ncbi request reprint Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines
    C K Lapham
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Science 274:602-5. 1996
  9. pmc Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules
    H Golding
    Division of Viral Products, CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 69:6140-8. 1995
  10. pmc The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells
    H Golding
    Division of Virology, CBER, Food and Drug Administration, Bethesda, Maryland 20892
    J Virol 68:1962-9. 1994

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies
    H Golding
    Division of Viral Products, CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 15:149-59. 1999
    ..These data suggest that conformational changes in the CDR3 region of CD4-D1, induced by gp120 binding, may be involved in coreceptor association and thus play a positive role in the HIV-1 cell fusion process...
  2. pmc Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Virol 79:6791-800. 2005
    ..In summary, we have identified a novel peptide that closely mimics the MAb 2D7 epitope on CCR5. This peptide could be included as a potential vaccine candidate or to isolate 2D7-like human antibodies as entry inhibitors for R5 viruses...
  3. pmc Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 43:304-12. 2006
    ..Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide...
  4. ncbi request reprint Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model
    Clement A Meseda
    Laboratory of DNA Viruses, Division of Viral Products, HFM 457 Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, Bethesda, MD 20892, USA
    Virology 339:164-75. 2005
    ..In addition, both Dryvax and various MVA vaccination protocols elicited antibody responses to the extracellular enveloped form of the virus and afforded protection against a lethal intranasal challenge with vaccinia virus WR...
  5. ncbi request reprint CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Biol Chem 280:29570-7. 2005
    ..The elucidation of the functional C-18-binding mechanism may help in the rational design of novel antiviral agents against HIV...
  6. ncbi request reprint Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A, Rm 1A21, 8800 Rockville Pike, Bethesda, MD, 20892, USA
    Blood 102:3280-6. 2003
    ..These data support the further development of C-18 derivatives as HIV-1 inhibitors for preventing HIV-1 transmission and for postexposure prophylaxis...
  7. pmc Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates
    Hana Golding
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A Room 1A21, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 76:6780-90. 2002
    ..They also indicate that six-helix bundles can form prior to fusion and that the lag time before fusion occurs may include the time needed to accumulate preformed six-helix bundles at the fusion site...
  8. ncbi request reprint Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines
    C K Lapham
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Science 274:602-5. 1996
    ..401 molecules from their membranes. Together these data provide evidence for physical association between fusin and the CD4-gp120 complex on cell membranes...
  9. pmc Phorbol ester-induced down modulation of tailless CD4 receptors requires prior binding of gp120 and suggests a role for accessory molecules
    H Golding
    Division of Viral Products, CBER, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 69:6140-8. 1995
    ....
  10. pmc The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells
    H Golding
    Division of Virology, CBER, Food and Drug Administration, Bethesda, Maryland 20892
    J Virol 68:1962-9. 1994
    ..These findings suggest a novel approach for identification of accessory molecules involved in fusion and may have implications for the development of antiviral agents...
  11. ncbi request reprint Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection
    M Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Blood 96:3109-17. 2000
    ....
  12. pmc CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor
    S Lee
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 74:6946-52. 2000
    ..Our data provide the first evidence that CCR8 functions as an HIV-1 coreceptor on primary human cells and suggest that CCR8 may contribute to HIV-1-induced thymic pathogenesis...
  13. pmc Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein
    D S Dimitrov
    Section on Membrane Structure and Function, National Cancer Institute, Bethesda, Maryland 20892
    J Virol 66:132-8. 1992
    ....
  14. ncbi request reprint Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5
    C K Lapham
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Nat Med 5:303-8. 1999
    ....
  15. pmc Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time
    H Golding
    Division of Virology, Food and Drug Administration, National Cancer Institute, Bethesda, Maryland 20892
    J Virol 67:6469-75. 1993
    ..We hypothesize that the long lag time is due to the inability of the CD4.CD8-gp120-gp41 complex to undergo the rapid conformational changes which occur during the fusion mediated by wild-type CD4...
  16. ncbi request reprint LFA-1 adhesion molecules are not involved in the early stages of HIV-1 env-mediated cell membrane fusion
    H Golding
    Division of Virology, CBER, FDA, Bethesda, MD
    AIDS Res Hum Retroviruses 8:1593-8. 1992
    ..These findings demonstrate that the adhesion molecule LFA-1 does not play a crucial role in the early events of HIV-1 env-mediated cell membrane fusion, but may contribute to the later events leading to giant cell formation...
  17. ncbi request reprint Initial stages of HIV-1 envelope glycoprotein-mediated cell fusion monitored by a new assay based on redistribution of fluorescent dyes
    D S Dimitrov
    Section on Membrane Structure and Function, NCI, NIH, Bethesda, MD 20892
    AIDS Res Hum Retroviruses 7:799-805. 1991
    ..The ability of those CEM variants to take part in HIV env-mediated membrane fusion did not correlate with their capacity to form syncytia. These findings indicate that additional steps are needed to form syncytia after membrane fusion...
  18. ncbi request reprint CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection
    O Shapira-Nahor
    Peptide and Immunochemistry Unit, National Institute of Dental Research, National Institute of Health, Bethesda, Maryland 20892
    Cell Immunol 128:101-17. 1990
    ..These data suggest that the CD4 region (74-95) participates in the CD4-mediated binding and/or internalization of HIV-I virion...
  19. ncbi request reprint Immunity and protection against Brucella abortus
    B Golding
    Division of Hematology, Office of Blood and Blood Research, Center for Biologics Research and Review, Food and Drug Administration, 1401 Woodmont, Rockville Pike, MD 20852, USA
    Microbes Infect 3:43-8. 2001
    ..The response against B. abortus involves the whole gamut of the immune system, from innate to adaptive immunity resulting from stimulation of antigen-presenting cells, NK cells, CD4(+) and CD8(+) T cells, and B cells...
  20. ncbi request reprint Interactions of CD4+ plasma membrane vesicles with HIV-1 and HIV-1 envelope glycoprotein-expressing cells
    A Puri
    Section on Membrane Structure and Function, NCI, NIH, Bethesda, Maryland 20892
    J Acquir Immune Defic Syndr 5:915-20. 1992
    ..The CD4 PMVs were more effective in inhibiting syncytia formation than sCD4. These results demonstrate that CD4 PMVs could be used to study the mechanisms of HIV-1 envelope-mediated fusion and have the potential to inactivate HIV-1...
  21. ncbi request reprint CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand
    C R Yu
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 164:1293-305. 2000
    ..The study of CCR9A and CCR9B should enhance our understanding of the role of the chemokine system in T cell biology, particularly during the stages of thymocyte development...
  22. ncbi request reprint CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection
    M B Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 161:3103-13. 1998
    ..Our data provide strong evidence that CXCR4 and CCR5 function as coreceptors for HIV-1 infection of human thymocytes...
  23. pmc Human peripheral blood T cells, monocytes, and macrophages secrete macrophage inflammatory proteins 1alpha and 1beta following stimulation with heat-inactivated Brucella abortus
    M Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 69:3817-26. 2001
    ....
  24. ncbi request reprint Correlation between kinetics of soluble CD4 interactions with HIV-1-Env-expressing cells and inhibition of syncytia formation: implications for mechanisms of cell fusion and therapy for AIDS
    D S Dimitrov
    Section of Membrane Structure and Function, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    AIDS 6:249-56. 1992
    ..To study the kinetics of the interactions between soluble (s) CD4 and HIV-1-Env-expressing cells in relation to subsequent events leading to cell fusion and inhibition of syncytia formation...
  25. ncbi request reprint Study of viral replication in HIV-1-infected CEM T-cell subclones which are reduced in their ability to form syncytia
    M F Gruber
    Division of Virology, Food and Drug Administration, Bethesda, MD 20892
    AIDS Res Hum Retroviruses 8:1139-46. 1992
    ..Thus, the EMS-mutagenized subclones may provide a tool to study host cell factors required for the establishment of a productive HIV-1 infection and responsiveness to TNF alpha...
  26. pmc Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1
    O Scharf
    Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 75:6558-65. 2001
    ..The results of this study have implications for the improvement of passive immunization with polyclonal or monoclonal antibodies and suggest that HIV-1 vaccines which induce high-titer IgG3 responses could be advantageous...
  27. ncbi request reprint Increased CXCR4-dependent HIV-1 fusion in activated T cells: role of CD4/CXCR4 association
    Marina Zaitseva
    Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29B, Room 4NN06, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Leukoc Biol 78:1306-17. 2005
    ..The CD4-CXCR4 complexes may shuttle between late endosomes and the cell surface...
  28. pmc Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies
    Surender Khurana
    Division of Viral Products, Center for Biologics Evaluation and Research CBER, FDA, Bethesda, MD 20892, USA
    J Virol 80:2092-9. 2006
    ..The new HIV-SELECTEST is a simple but robust diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide...
  29. ncbi request reprint Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity
    Yong He
    Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 196:1026-32. 2007
    ..These findings demonstrate that A27 antibodies do not represent the major fraction of neutralizing activity in VIG and suggest that immunity may be augmented by vaccines and immune globulins that include strong antibody responses to A27...
  30. ncbi request reprint Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii
    Felix Yarovinsky
    Immunobiology Section, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Biol Chem 279:53635-42. 2004
    ..These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent...
  31. ncbi request reprint Systemic and mucosal immunity in rhesus macaques immunized with HIV-1 peptide and gp120 conjugated to Brucella abortus
    Nancy Eller
    Laboratory of Plasma Derivatives, Division of Hematology, Office of Blood Research and Review, Bethesda, MD 20892, USA
    J Med Primatol 33:167-74. 2004
    ....
  32. ncbi request reprint CXCR4 heterogeneity in primary cells: possible role of ubiquitination
    Cheryl K Lapham
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Leukoc Biol 72:1206-14. 2002
    ..Our data indicate that ubiquitination may contribute to CXCR4 heterogeneity and suggest roles for proteasomes and lysosomes in the constitutive turnover of CXCR4 in primary human cells...
  33. ncbi request reprint Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques
    Yvette Edghill-Smith
    Laboratory of Receptor Biology and Gene Expression, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 5055, USA
    J Infect Dis 188:1181-91. 2003
    ....
  34. ncbi request reprint HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors
    Marina Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1614:51-61. 2003
    ..We also summarize the classes of coreceptor inhibitors under development...
  35. ncbi request reprint Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus
    Basil Golding
    Laboratory of Plasma Derivatives, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Woodmont, Rockville Pike, Rockville, MD 20852, USA
    Vaccine 20:1445-50. 2002
    ..This approach may protect individuals from HIV-1 infection and reduce transmission from infected individuals to their sexual partners and offspring...
  36. ncbi request reprint Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is mediated in part by a cAMP-responsive element
    Anthony D Cristillo
    Laboratory of Lymphocyte Biology, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892, USA
    FASEB J 16:354-64. 2002
    ..The cAMP-dependent up-regulation of CXCR4 mRNA results in increased CXCR4 intracellular and cell surface protein expression as well as increased HIV infectivity...
  37. ncbi request reprint Stromal-derived factor 1 expression in the human thymus
    Marina Zaitseva
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, and Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:2609-17. 2002
    ..It was further demonstrated that uptake of apoptotic thymocytes by immature DC induced an increase in CXCR4 expression and SDF-1-mediated chemotaxis. Our data suggest a role for SDF-1 in the elimination of apoptotic thymocytes...
  38. ncbi request reprint Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection
    Virginia L Kan
    Infectious Diseases Section, Veterans Affairs Medical Center, Washington, DC, USA
    AIDS 21:521-4. 2007
    ..Therefore, after robust vaccination, neutralizing antibodies are maintained for prolonged times despite CD4 cell depletion...
  39. ncbi request reprint Subunit recombinant vaccine protects against monkeypox
    Jean Michel Heraud
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 177:2552-64. 2006
    ..Their identification may guide future efforts to develop simpler, safer, and more effective vaccines for monkeypox and smallpox...
  40. ncbi request reprint Monitoring of human immunological responses to vaccinia virus
    Richard Harrop
    Oxford BioMedica UK Ltd, Oxford, United Kingdom
    Methods Mol Biol 269:243-66. 2004
    ..The use of reliable immunological assays is vital in assessing the potential efficacy of new vaccines to protect against smallpox infection...
  41. ncbi request reprint Development of a novel vaccinia-neutralization assay based on reporter-gene expression
    Jody Manischewitz
    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drugs Administration, Bethesda, Maryland 20892, USA
    J Infect Dis 188:440-8. 2003
    ..The new assay will serve as an important tool both for preclinical and clinical trials of new smallpox vaccines and for evaluation of therapeutic agents to treat vaccine-associated adverse reactions...
  42. ncbi request reprint Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus
    Yvette Edghill-Smith
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, 41 D804, Bethesda, Maryland 20892, USA
    Nat Med 11:740-7. 2005
    ..Thus, vaccines able to induce long-lasting protective antibody responses may constitute realistic alternatives to the currently available smallpox vaccine (Dryvax)...
  43. ncbi request reprint Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge
    Yvette Edghill-Smith
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infect Dis 191:372-81. 2005
    ..Thus, vaccination strategies that bypass CD4(+) cell help are needed to elicit IgG antibodies with high affinity and adequate tissue distribution and to restore protection against smallpox in severely immunocompromised individuals...
  44. ncbi request reprint Production of recombinant proteins by vaccinia virus in a microcarrier based mammalian cell perfusion bioreactor
    Nicole A Bleckwenn
    Biotechnology Unit, NIDDK, National Institutes of Health, DHHS, Bldg 14A Rm 173, MSC 5522, 9000 Rockville Pike, Bethesda, Maryland, USA
    Biotechnol Bioeng 90:663-74. 2005
    ..Also, biological activity was assayed, resulting in an ID50 of 3.1 microg/mL, which is comparable to previous reports...